The Technology Development Board has sanctioned ₹86 crore for Bengaluru-based Peptris Technologies to boost AI-driven drug discovery. The funding will support the ₹172 crore 'VIGOR' project, aimed at moving four drug candidates from lab models toward clinical testing. As a private firm, Peptris is not listed on the stock exchange, but the partnership signals a significant step for India’s biotech innovation.
The Technology Development Board (TDB), operating under India’s Department of Science and Technology, has committed ₹86 crore to support the VIGOR project, an initiative led by Bengaluru-based biotech startup Peptris Technologies. The total cost of this program is estimated at ₹172 crore, with the government funding structured as optionally convertible debt. This type of financial arrangement serves as a loan that can eventually convert into equity, allowing the company to access capital while managing its balance sheet.
The core objective of the VIGOR project is to fast-track the development of four distinct drug candidates. These molecules are currently in early-stage laboratory development, and the project aims to advance them to a stage where they are ready for formal clinical trials. By using artificial intelligence to identify and refine these molecules, the company intends to shorten the time often required in traditional drug discovery processes.
For the Indian biotechnology sector, this move reflects an ongoing effort to reduce dependence on external drug development pipelines. Artificial intelligence is increasingly viewed as a tool to improve the efficiency of identifying potential treatments for conditions such as diabetes, neuropathy, and certain types of cancer. However, the path from a digital model to a physical medicine is fraught with significant hurdles.
Investors and observers should note that Peptris Technologies is a private startup, meaning it does not have shares traded on the National Stock Exchange or the Bombay Stock Exchange. While the government backing is a vote of confidence, the company remains subject to the inherent risks of the pharmaceutical industry. Drug development is capital-intensive and possesses a high failure rate; many promising candidates fail during preclinical and early clinical testing due to unexpected scientific or safety issues.
Furthermore, the project relies on external contract research organizations to conduct the physical, or wet-lab, experiments needed to validate the AI models. This reliance introduces execution risks, as the quality and timelines of these experiments depend on third-party providers. The success of the VIGOR project will ultimately depend on the company's ability to bridge the gap between its computational discovery platform and reliable empirical testing.
Looking ahead, the next important updates for the sector and stakeholders will involve the company's ability to meet specific technical milestones. Monitoring whether these four candidates successfully pass their upcoming validation stages will be essential to gauge the effectiveness of the government’s investment in indigenous AI-led therapeutic solutions.